metricas
covid
Buscar en
Clinics
Toda la web
Inicio Clinics Prognostic factors of the short-term outcomes of patients with hepatitis B virus...
Información de la revista
Vol. 72. Núm. 11.
Páginas 686-692 (enero 2016)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Visitas
699
Vol. 72. Núm. 11.
Páginas 686-692 (enero 2016)
CLINICAL SCIENCE
Open Access
Prognostic factors of the short-term outcomes of patients with hepatitis B virus-associated acute-on-chronic liver failure
Visitas
699
Qing LeiI,#, Kangjian AoI,#, Yinhua ZhangI, Deqiang MaI, Deping DingI, Changzheng KeI, Yue ChenI, Jie LuoIII,
, Zhongji MengI,II,
I Department of Infectious Diseases, Taihe Hospital, Hubei University of Medicine, Hubei, Shiyan, 442000, China
II Institute of Biomedical Research, Taihe Hospital, Hubei University of Medicine, Hubei, Shiyan, 442000, China
III Center for Evidence-Based Medicine and Clinical Research, Taihe Hospital, Hubei University of Medicine, Hubei, Shiyan, 442000, China
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (2)
OBJECTIVE:

To investigate the impact of the baseline status of patients with hepatitis B virus-associated acute-on-chronic liver failure on short-term outcomes.

METHODS:

A retrospective study was conducted that included a total of 138 patients with hepatitis B virus-associated acute-on-chronic liver failure admitted to the Department of Infectious Diseases, Taihe Hospital, Hubei University of Medicine, from November 2013 to October 2016. The patients were divided into a poor prognosis group (74 patients) and a good prognosis group (64 patients) based on the disease outcome. General information, clinical indicators and prognostic scores of the patients' baseline status were analyzed, and a prediction model was established accordingly.

RESULTS:

Elder age, treatment with artificial liver support systems and the frequency of such treatments, high levels of white blood cells, neutrophils, neutrophil count/lymphocyte count ratio, alanine aminotransferase, gamma-glutamyl transferase, total bilirubin, urea, and prognostic scores as well as low levels of albumin and sodium were all significantly associated with the short-term outcomes of hepatitis B virus-associated acute-on-chronic liver failure. The predictive model showed that logit (p) = 3.068 + 1.003 × neutrophil count/lymphocyte count ratio - 0.892 × gamma-glutamyl transferase - 1.138 × albumin - 1.364 × sodium + 1.651 × artificial liver support therapy.

CONCLUSION:

The neutrophil count/lymphocyte count ratio and serum levels of gamma-glutamyl transferase, albumin and sodium were independent risk factors predicting short-term outcomes of hepatitis B virus-associated acute-on-chronic liver failure, and the administration of multiple treatments with artificial liver support therapy during the early stage is conducive to improved short-term outcomes.

KEYWORDS:
Hepatitis B Virus
Acute-on-Chronic Liver Failure
Prognosis
Texto completo
INTRODUCTION

Acute-on-chronic liver failure (ACLF) refers to a group of complex clinical syndromes characterized by acute severe liver function damage (caused by a number of acute triggering factors) in patients with chronic liver disease, complicated by the failure of one or more organs. ACLF is the most common type of liver failure in China and has a high mortality rate of 50-90% 1. The predominant causes of ACLF differ in different parts of the world. In China, the most important cause is infection with hepatitis virus, especially hepatitis B virus (HBV) 2. The pathogenesis of HBV-ACLF has not been well elucidated, although the “three-shock” hypothesis (i.e., immune injury, ischemia and hypoxia and endotoxin-induced damage) is currently the most generally recognized hypothesis 3.

For severe ACLF, the only effective treatment is liver transplantation. However, due to the shortage of resources, the demand for liver transplantation cannot be met. At present, the treatment strategy for HBV-ACLF is comprehensive combination with internal medicine, anti-viral medications and artificial liver support therapy 4. Artificial liver support therapy can temporarily replace part of the liver function and prevent further exacerbation of liver failure by removing toxic substances and metabolites from the serum, improving the microenvironment for liver cell regeneration and liver function repair. However, the efficacy of artificial liver support therapy for liver failure remains controversial 5–7.

The early identification, accurate diagnosis and prognostic evaluation of ACLF can provide a guiding basis for active and effective treatment. Therefore, a better understanding of prognostic factors and more precise prognostic evaluation systems for ACLF are in urgent need. A variety of factors can affect the progression and prognosis of ACLF. Many prognostic scoring systems are available for predicting the outcomes of ACLF, including the Child-Turcotte-Pugh (CTP) system, the model for end-stage liver disease (MELD) and the MELD-sodium (MELD-Na). Each scoring system has certain limitations given that not all of the influencing factors can be included in the individual assessment. The integrated MELD (iMELD) is a new scoring system that features the addition of two independent ACLF prognostic risk factors, age and serum Na levels, to the MELD scoring system 8. In addition, the albumin-bilirubin (ALBI) grading system is a recently developed scoring system to assess liver function 9. Several studies have compared the predictive ability of different scoring systems in ACLF 10–12. Comparisons of the predictive abilities of the CTP, MELD, MELD-Na, iMELD and ALBI scoring systems for the prognosis of HBV-ACLF are rarely reported. Attempts to analyze the impact of clinical parameters and the combined prognostic abilities of these parameters on ACLF prognosis have provided inconsistent results due to differences in study subjects, study phases and follow-up periods 13–15. The integration of general information, clinical indicators and a prognostic scoring system may better predict the short-term outcomes of patients with HBV-ACLF.

In this study, a retrospective investigation was carried out in HBV-ACLF patients admitted to the Department of Infectious Diseases, Taihe Hospital, Hubei University of Medicine from November 2013 to October 2016. General patient information, laboratory indicators and prognostic scores at baseline of HBV-ACLF patients with different prognoses were analyzed, and the factors that influenced the short-term outcomes of HBV-ACLF were investigated.

PATIENTS AND METHODSPatient selection

Based on the clinical data in the medical record system of Taihe Hospital, Hubei University of Medicine, a retrospective analysis was conducted in patients admitted to the Department of Infectious Diseases from November 2013 to October 2016 who met the criteria of HBV-ACLF during their hospitalization. The data from the medical records of the selected patients were input in the form of case reports and verified with the clinical data system in our hospital. All of the patients were given comprehensive supportive treatment of internal medicine after admission to the hospital, including anti-viral therapy with nucleoside analogs. Artificial liver support therapy was optional based on the patient's condition and willingness. The end point of the observation in this study was the time of discharge or in-hospital death of the patient. The study protocol was approved by the Ethics Committee of Taihe Hospital, Hubei University of Medicine.

Inclusion and exclusion criteria

The diagnostic criteria for HBV-ACLF were based on the “Guidelines for the Prevention and Treatment of Chronic Hepatitis B” of China issued in 2015 and the “Guidelines for Diagnosis and Treatment of Liver Failure (2012 Edition)” of China. The exclusion criteria included patients complicated with other forms of viral hepatitis, alcoholic liver disease, autoimmune liver disease, drug-induced liver injury, associated tumors or severe organ disease other than hepatitis B.

General information

The general information included gender, age, with/without (w/wo) liver cirrhosis, rebound after withdrawal of anti-viral drugs, complication with ascites at admission and the acceptance and frequency of artificial liver support therapy. All of this information was retrieved from the medical record system of Taihe Hospital.

Clinical indicators

The following measurements were performed using venous blood collected on the first day of admission or on the morning following admission: baseline white blood cell count (WBC), absolute neutrophil count (NE), absolute lymphocyte count (LY), NE:LY ratio (NE/LY), platelet count (PLT), levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT), albumin (Alb), total bilirubin (TBil), urea (Urea), and creatinine (Cr), prothrombin time (PT), prothrombin activity (PTA), activated partial thromboplastin time (APTT), the international normalized ratio (INR) and serum Na levels. All results were retrieved from the clinical database.

Prognostic score

The prognostic scoring systems included the CTP, MELD, MELD-Na, iMELD and ALBI. The CTP score is the cumulative result of the scores for five items (ascites, hepatic encephalopathy, TBil, Alb and PT extension time), with 1-3 points for each item and a maximum of 15 points 16, 17. The equation for the MELD score is as follows: 3.8 LN (TBil [mg/dL]) + 11.2 LN (INR) + 9.6 LN (Cr [mg/dL]) + 6.4 × cause (0 for cholestatic or alcoholic liver diseases and 1 for all others); the result is a rounded integer 18. The equation for the MELD-Na score is as follows: MELD + 1.59 × (135 - Na), wherein Na is 135 mmol/L if Na > 135 mmol/L and 120 mmol/L if Na < 120 mmol/L 19. The equation for the iMELD score is as follows: MELD + (0.3 × Age) - (0.7 × Na) + 100 8. The equation for the ALBI score is as follows: (log10TBil [µmol/L] × 0.66) + (Alb [g/L] × - 0.085) 9.

Prognostic criteria

The prognostic criteria in this study were based on the ACLF clinical improvement criteria in “Guidelines for Diagnosis and Treatment of Liver Failure (2012 Edition)” of China 2. A good prognosis needs to meet all of the following conditions simultaneously: 1) the clinical symptoms are significantly improved and hepatic encephalopathy has disappeared; 2) signs of jaundice and ascites are significantly improved; and 3) liver function is significantly improved (TBil <5 ULN, PTA >40%). The patients who died, whose condition became more advanced, and those who still experienced ACLF were included in the poor prognosis group.

Data processing

All data included in this study were retrieved from the electronic medical record system of Taihe Hospital and validated using the clinical data system. Cases with missing or incomplete data, such as AFP data, were not included in the study.

Statistical analysis

Statistical Package for the Social Sciences (SPSS) 17.0 software was used for the statistical analysis. The measurement data were first tested for a normal distribution. Data that showed a normal distribution were represented as ±s and were analyzed using the t-test. The data that were not normally distributed were represented as medians (P25 and P75) and analyzed using the nonparametric rank sum test. The count data among different groups were analyzed using the χ2 test. The area under the receiver operating characteristic (ROC) curve was used to assess the predictive power of the five scoring systems for the prognosis of HBV-ACLF, and the cut-off value of the continuous variable was calculated. The method of likelihood-ratio-forward-selection in non-conditional binary logistic regression analysis was used to obtain the independent risk factors and to establish a predictive model. The threshold used for statistical significance was p<0.05.

RESULTSCase enrollment

A total of 171 patients with HBV-ACLF were admitted to the department of infectious disease of Taihe Hospital from November 2013 to October 2016. A total of 138 patients were selected according to the inclusion and exclusion criteria, including 111 males and 27 females with an average age of 45.80±11.01 years. There were 74 cases in the poor prognosis group, accounting for 53.6%, and 64 cases in the good prognosis group, accounting for 46.4%. Of the cases in the poor prognosis group, 59 cases showed ACLF; 15 cases were in the pre-ACLF state at admission. In the good prognosis group, the corresponding numbers were 45 cases and 19 cases, respectively (Figure 1).

Figure 1.

Case screening and enrollment. No statistically significant difference was observed between the poor prognosis group and the good prognosis group in terms of disease stage at admission.

(0.07MB).
General information of the patients

The average age of the patients in the poor prognosis group was significantly higher than that in the good prognosis group (48.08±9.08 years vs. 43.16±12.44 years, p=0.01). The number of patients who received artificial liver support therapy and the frequencies of artificial liver support therapy in the good prognosis group were significantly higher than in the poor prognosis group (p<0.01). There were no significant differences between the two groups with respect to sex, rebound after anti-viral drug withdrawal or the complications of cirrhosis and ascites (Table 1).

Table 1.

General information of the patients.

  Good prognosis  Poor prognosis  Statistics value  p value 
Age (years)  43.16±12.44  48.08±9.08  t′ = 2.621  0.010 
Gender (male/female)  52/12  59/15  χ2 = 0.05  0.822 
W/wo liver cirrhosis  19/45  32/42  χ2 = 2.707  0.100 
W/wo drug-withdrawal rebound  6/5  10/22  χ2 = 1.035  0.309 
W/wo ascites  41/23  55/19  χ2 = 1.707  0.191 
W/wo ALST  54/10  36/38  χ2 = 19.31  0.000 
Number of treatments  1.62 (0.79, 2.55)  0.64 (0, 1.61)  Z = -4.422  0.000 

Note: W/wo indicates with/without; ALST is the abbreviation of artificial liver support therapy.

The baseline clinical indicators for HBV-ACLF patients with different prognoses

The WBC, NE, NE/LY, ALT, GGT, TBil and Urea scores/levels were significantly higher in the poor prognosis group (p<0.05), while the Alb and Na levels in the good prognosis group were significantly higher than in the poor prognosis group (p<0.01). There were no statistically significant differences between the two groups in terms of the other clinical indicators, including LY, PLT, AST, Cr, PT, APTT and INR (Table 2).

Table 2.

Clinical indicators of the baseline status of the patients.

  Good prognosis  Poor prognosis  Statistics value  p value 
WBC (× 1012/L)  5.31 (4.12, 6.79)  6.40 (4.48, 9.07)  Z = -2.291  0.022 
NE (× 1012/L)  3.16 (2.28, 4.99)  4.03 (2.86, 6.57)  Z = -2.248  0.025 
LY (× 1012/L)  1.13 (0.84, 1.43)  1.21±0.63  Z = -0.566  0.572 
NE/LY  2.70 (1.79, 5.37)  3.96 (2.93, 6.69)  Z = -2.517  0.012 
PLT (× 1012/L)  88.0 (65.25, 125.67)  85.0 (46.0, 122.33)  Z = -1.087  0.277 
ALT (U/L)  507.5 (175.5, 902.0)  198.0 (81.0, 674.0)  Z = -2.589  0.01 
AST (U/L)  289.5 (124.0, 767.5)  210.0 (95.67, 424.0)  Z = -1.543  0.123 
GGT (U/L)  108.5 (62.5, 159.5)  66.0 (47.0, 125.0)  Z = -2.735  0.006 
Alb (g/L)  33.74±5.174  30.71±5.56  t = -3.30  0.001 
TBil (μmol/L)  234.24±106.27  301.62±144.45  t′ = 3.147  0.002 
Urea (mmol/L)  4.17 (2.98, 5.44)  4.54 (3.54, 7.52)  Z = -2.002  0.045 
Cr (μmol/L)  55.75 (42.7, 77.95)  56.95 (42.7, 85.5)  Z = -0.431  0.666 
Na (mmol/L)  138.91±4.209  136.07±6.33  t′ = -3.136  0.002 
PT (s)  22.45 (18.5, 26.03)  25.0 (18.6, 30.9)  Z = -1.738  0.082 
PTA (%)  28.27 (22.64, 36.97)  26.37±12.80  Z = -1.964  0.05 
APTT (s)  52.83±14.70  56.33±18.69  t′ = 1.231  0.22 
INR  1.98±0.62  2.05 (1.6, 2.72)  Z = -1.642  0.101 

Note: Normally distributed data are represented as ±s. Non-normally distributed data are represented as medians (P25 and P75).

High CTP, MELD, MELD-Na, iMELD and ALBI scores all predict poor short-term outcomes for HBV-ACLF patients

Compared with the patients with a good prognosis, the patients with a poor prognosis showed significantly higher scores for the CTP, MELD, MELD-Na, iMELD and ALBI prognostic systems (p<0.05) (Table 3). The prognosis of HBV-ACLF was well predicted by these five types of prognostic scores. The areas under the ROC curves of the CTP, MELD, MELD-Na, iMELD and ALBI prognostic systems were 0.672, 0.641, 0.656, 0.699, and 0.682, respectively (Table 4, Figure 2).

Table 3.

Prognostic scores of the patients at baseline.

  Good prognosis  Poor prognosis  Statistics value  p value 
CTP score  10.11±1.78  11.2±1.68  t = 3.706  0.000 
MELD score  18.08±7.10  21.58±7.39  t = 2.828  0.005 
MELD-Na score  18.95±7.7  24.18±10.11  t = 3.573  0.000 
iMELD score  33.79±9.15  40.75±9.90  t = 4.268  0.000 
ALBI score  -1.34±0.52  -1.01±0.54  t = 3.639  0.000 
Table 4.

Comparison of the five types of prognostic scores.

AreaSensitivity (%)Specificity (%)Std. errorAsymptotic Sig.95% C.I.
Lower  Upper 
CTP  0.672  47.3  79.7  0.045  0.000  0.593  0.761 
MELD  0.641  56.8  71.9  0.047  0.004  0.549  0.733 
MELD-Na  0.656  41.9  85.9  0.046  0.002  0.565  0.746 
iMELD  0.699  74.3  62.5  0.045  0.000  0.611  0.786 
ALBI  0.682  62.2  67.2  0.045  0.000  0.594  0.771 
Logit(p)  0.656  62.2  64.1  0.046  0.002  0.565  0.746 
Figure 2.

ROC curves for CTP, MELD, MELD-Na, iMELD, ALBI score and logit (p) curve.

(0.04MB).
Independent prognostic factors and novel prediction model for HBV-ACLF

The different measures of general patient information, clinical indicators and prognostic scores at baseline for the two groups were assigned corresponding values for non-conditional binary logistic regression analysis. The cut-off values of the continuous variables were calculated using the area under the ROC curve (Tables 5 and 6) to establish the following prediction model: logit (p) = 3.068 + 1.003 × NE/LY - 0.892 × GGT - 1.138 × Alb -1.364 × Na + 1.651 × artificial liver support therapy. The area under the ROC curve was 0.656, with a specificity of 64.1% and sensitivity of 62.2%. NE/LY, GGT, Alb, Na and artificial liver support therapy were the independent factors influencing the short-term outcomes of HBV-ACLF (Table 7).

Table 5.

Area under the ROC curve and the cut-off value of each variable.

Cut-off valuec-statistic95% CI
Lower  Upper 
Age  43.5  0.643  0.549  0.738 
WBC  6.75  0.613  0.52  0.707 
NE  5.635  0.611  0.517  0.705 
NE/LY  2.947  0.624  0.53  0.719 
ALT  127.5  0.372  0.279  0.465 
GGT  76  0.365  0.272  0.457 
Alb  34.85  0.343  0.252  0.435 
TBil  251.2  0.632  0.54  0.725 
Urea  6.365  0.599  0.505  0.693 
Na  136.3  0.361  0.268  0.454 
CTP  11.5  0.672  0.593  0.761 
MELD  21.448  0.641  0.549  0.733 
MELD-Na  25.636  0.656  0.565  0.746 
iMELD  34.705  0.699  0.611  0.786 
ALBI  -1.119  0.682  0.594  0.771 
Table 6.

Variable assignment.

Assignment
Age  ≤ 43.5  > 43.5 
WBC  ≤ 6.75  > 6.75 
NE  ≤ 5.635  > 5.635 
NE/LY  ≤ 2.947  > 2.947 
ALT  ≤ 127.5  > 127.5 
GGT  ≤ 76  > 76 
Alb  ≤ 34.85  > 34.85 
TBil  ≤ 251.2  > 251.2 
Urea  ≤ 6.365  > 6.365 
Na  ≤ 136.3  > 136.3 
MELD  ≤ 21.448  > 21.448 
MELD-Na  ≤ 25.636  > 25.636 
iMELD  ≤ 34.705  > 34.705 
CTP  ≤ 11.5  > 11.5 
ALBI  ≤ -1.119  > -1.119 
Artificial liver support therapy (ALST)  No  Yes 
Prognosis  Good prognosis  Poor prognosis 
Table 7.

Logistic regression analysis results.

BSEWaldSigExp(B)95% CI for Exp(B)
Lower  Upper 
NE/LY  1.003  0.444  5.109  0.024  2.728  1.143  6.512 
GGT  -0.892  0.428  4.338  0.037  0.41  0.177  0.949 
Alb  -1.138  0.511  4.951  0.026  0.321  0.118  0.873 
Na  -1.364  0.455  8.979  0.003  0.256  0.105  0.624 
Artificial liver support therapy  1.651  0.473  12.161  0.000  5.21  2.06  13.174 
Constant term  3.068  1.441  4.535  0.033  21.489     
DISCUSSION

HBV-ACLF is a common fatal clinical disease characterized by a large number of necrotic liver cells, a complex pathological mechanism and rapid progression. The results of this study showed that many factors are closely related to the short-term outcomes of this condition.

Age has been shown to be closely related to the severity of liver diseases and serves as an independent prognostic factor for end-stage liver disease 8,20. Studies have found that the short-term mortality rate of patients with ACLF is positively correlated with patient age 21. In this study, the average age of the patients with a poor prognosis was significantly higher than that in the patients with a good prognosis, suggesting that age is an important prognostic factor in HBV-ACLF.

As an important supportive treatment measure for the recovery of liver function in patients with liver failure, artificial liver therapy can improve the conditions and opportunities for the regeneration of liver cells and the recovery of liver function. Artificial liver support systems take various forms, and their efficacy in treating liver failure remains controversial. Previous studies have shown that artificial liver support therapy can only improve the bilirubin level and hepatic encephalopathy of the patients, with no effect on the survival rate 5. There are also studies indicating that artificial liver support therapy can reduce the short-term mortality rate of patients with ACLF, whereas its impact on long-term survival is uncertain 6. Considering that the above results are for different types of artificial liver support therapy and different periods of application, plasma replacement therapy was primarily applied in this study. The number of patients who received artificial liver support therapy and the frequency of this therapy were significantly higher in the good prognosis group than in the poor prognosis group. Moreover, artificial liver support therapy was an independent factor for the short-term outcomes of HBV-ACLF. Therefore, the early active implementation of treatment combined with artificial liver support therapy can significantly improve the short-term outcomes of patients with HBV-ACLF.

WBC, NE and the NE/LY ratio are often associated with inflammation and infection. According to the “three-shock” hypothesis, inflammation is an important step in the development of HBV-ACLF 3. At the same time, studies have shown that infection can induce and promote the development of ACLF 22, and the severity of inflammation is significantly correlated with the prognosis of ACLF 23 The study of Li et al 13 showed that WBC is an independent risk factor for HBV-ACLF. In this study, the WBC, NE count and NE/LY ratio of the patients with a poor prognosis were significantly higher than those of the patients with a good prognosis, suggesting that, in addition to WBC, a high NE count and NE/LY ratio are also important prognostic factors for HBV-ACLF.

The following events occur in cases of liver failure: liver cell necrosis occurs; liver function is impaired; enzyme synthesis is reduced; disorders in detoxification, excretion and transport capacity occur; bilirubin, amino acids and other substances are released into the blood and accumulate; serum bilirubin and transaminase levels increase; and the synthesis of proteins and coagulation factors decreases, resulting in decreased Alb levels and the development of coagulation disorders. In the present study, liver function and coagulation function were abnormal in both groups, and the levels of ALT, GGT, TBil and Alb all showed significant differences between the two groups. Of these measures, GGT and Alb were independent risk factors for poor prognosis of HBV-ACLF. However, a comparison of the baseline PTA of the patients in the two groups showed a significance level of p=0.05. Therefore, this difference was not considered statistically significant. Baseline PTA may be related to the patient's stage of disease at admission. Because the majority of patients in this study had reached the ACLF state at admission, with PTA ≤40%, the difference between the two groups was small. Changes and differences in coagulation can be further investigated and analyzed at different times and over different observation periods.

Ascites, hyponatremia and hepatorenal syndrome are common complications of ACLF. Complications such as refractory ascites, hyponatremia and renal injury are often interrelated and may continuously degenerate 2. In this study, the serum Na levels of patients in the poor prognosis group were significantly lower than those of the patients with a good prognosis. Low Na levels were an independent risk factor for poor prognosis of HBV-ACLF; this finding is consistent with the results of the studies of Zhang et al 15 and Shi et al 24. The results suggest that electrolytes should be closely monitored and electrolyte imbalances should be corrected during HBV-ACLF treatment.

In this study, the serum levels of urea were higher in the poor prognosis group than those in patients with good prognoses, whereas no significant difference in the level of Cr was found between the two groups. Accordingly, renal function damage may have a certain relationship with the prognosis of HBV-ACLF. However, the etiology of all patients included in this study was HBV infection. The diagnostic criteria for ACLF were based on the “Guidelines for Diagnosis and Treatment of Liver Failure (2012 Edition)” of China. In cases of ACLF associated with HBV infection, early organ damage is primarily manifested as liver function damage and coagulation dysfunction rather than as increased Cr levels.

Use of the prognostic evaluation system can help clinicians predict disease prognosis in the early stage of the disease and assess the severity of the disease, providing guidance in the choice of active and effective treatment. However, because each prognostic scoring system has limitations, this study for the first time compared the five scoring systems (CTP, MELD, MELD-Na, iMELD and ALBI) in HBV-ACLF patients with differing prognosis. The results showed that all five prognostic scoring systems demonstrated good predictive value for ACLF. The prognostic scores of the patients at baseline status in the poor prognostic group were significantly higher than those of the patients in the good prognosis group, suggesting that the prognosis of HBV-ACLF was significantly correlated with the prognostic scores at baseline status.

A novel prognostic scoring system was established according to the factors that affect the short-term outcomes of HBV-ACLF, as follows: logit (p) = 3.068 + 1.003 × NE/LY - 0.892 × GGT - 1.138 × Alb - 1.364 × Na + 1.651 × artificial liver support therapy. The sensitivity and specificity were 62.2% and 64.1%, respectively. The sensitivity of this novel predictive model was much higher than those of MELD-Na and MELD scores. Additionally, the area under the ROC curve of this predictive model was much larger than that of the MELD score, although it was smaller than that of iMELD score. Most importantly, except for serum Na, the parameters of NE/LY, GGT, Alb, and artificial liver support therapy were shown to be important factors that affect the short-term outcomes of HBV-ACLF as well. In addition to the indexes of liver function, complications such as infection were also included in this model. Thus, the novel predictive model was extremely suitable for ACLF patients in the end stage with multiple complications, especially those with an extremelyelevated INR, and this circumstance was restricted in evaluations using the iMELD, MELD-Na, and MELD scores.

Differences in study subjects, study phases and sample sizes may lead to different results. Although this study was a comprehensive study of factors that contribute to the short-term outcomes of HBV-ACLF, it had some limitations. First, all patients were enrolled from a single center, which may not reflect regional influences on the prognosis. Secondly, alpha fetal protein and a history of antiviral therapy were not examined in this study. Lastly, only short-term outcomes were analyzed. Multi-center studies over different observation periods are required to further research HBV-ACLF and to provide a better theoretical basis for its clinical diagnosis and treatment.

In conclusion, a variety of factors can affect the prognosis of HBV-ACLF patients. Older age, high WBC, NE, NE/LY, and TBil levels, renal dysfunction, hyponatremia, hypoproteinemia and high prognostic scores at baseline often suggest a poor prognosis. For patients with HBV-ACLF, within the context of anti-viral treatment and comprehensive internal medicine treatment, infection control should be strengthened and the stability of the patient's lab values, including the electrolyte balance, should be maintained. In addition, early active treatment combined with artificial liver support therapy is recommended. Further studies are needed to enhance our understanding of HBV-ACLF pathogenesis and reduce its morbidity and mortality.

AUTHOR CONTRIBUTIONS

Lei Q, Ke C, Chen Y, Luo J and Meng Z conceived and designed the study. Lei Q, Ao K, Zhang Y, Ma D, Ding D were responsible for the data collection. Lei Q analyzed the data and wrote the manuscript. Meng Z was responsible for the manuscript final revision.

ACKNOWLEDGMENTS

This work was partly supported by the National Natural Science Foundation of China (81541140), Natural Science Foundation of Hubei Province of China (2014CFB645), Research and Development Project of the Science and Technology Plan of Hubei Province (2011BCB030), Foundation for Innovative Research Team of Hubei University of Medicine (2014CXG05) and the Key Program for Precision Medicine of Taihe Hospital (2016JZ05).

REFERENCES
[1]
R Jalan , P Gines , JC Olson , RP Mookerjee , R Moreau , G Garcia-Tsao , et al.
Acute-on chronic liver failure.
[2]
Liver Failure And Artificial Liver Group CSOI, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association .
[Diagnostic and treatment guidelines for liver failure (2012 version)].
Zhonghua Gan Zang Bing Za Zhi, 21 (2013), pp. 177-183
[3]
YN Ye , ZL Gao .
[Three shock hypotheses that may induce liver failure].
Zhonghua Gan Zang Bing Za Zhi, 17 (2009), pp. 638-640
[4]
XY Liu , F Peng , YJ Pan , J Chen .
Advanced therapeutic strategies for HBV-related acute-on-chronic liver failure.
[5]
A Vaid , H Chweich , EM Balk , BL Jaber .
Molecular adsorbent recirculating system as artificial support therapy for liver failure: a meta-analysis.
[6]
Y Shen , XL Wang , B Wang , JG Shao , YM Liu , Y Qin , et al.
Survival Benefits With Artificial Liver Support System for Acute-on-Chronic Liver Failure: A Time Series-Based Meta-Analysis.
Medicine (Baltimore), 95 (2016),
[7]
JJ Chen , JR Huang , Q Yang , XW Xu , XL Liu , SR Hao , et al.
Plasma exchange-centered artificial liver support system in hepatitis B virus-related acute-on-chronic liver failure: a nationwide prospective multicenter study in China.
[8]
A Luca , B Angermayr , G Bertolini , F Koenig , G Vizzini , M Ploner , et al.
An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis.
[9]
PJ Johnson , S Berhane , C Kagebayashi , S Satomura , M Teng , HL Reeves , et al.
Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade.
J Clin Oncol, 33 (2015), pp. 550-558
[10]
C Li , S You , H Liu , W Liu , Z Wan , G Tang , et al.
[The value of the baseline MELD scores, MELD-Na scores and iMELD scores in short-term prognosis in hepatitis B virus related acute-on-chronic liver failure patients].
[11]
Y Shen , YM Liu , B Wang , YG Zhu , YY Wang , XL Wang , et al.
External validation and comparison of six prognostic models in a prospective cohort of HBV-ACLF in China.
Ann Hepatol, 15 (2016), pp. 236-245
[12]
Y Peng , X Qi , S Tang , H Deng , J Li , Z Ning , et al.
Child-Pugh, MELD, and ALBI scores for predicting the in-hospital mortality in cirrhotic patients with acute-on-chronic liver failure.
[13]
C Li , S Lyu , B Zhu , ZH Wan , WS Liu , L Guo , et al.
[Risk factors for short-term outcome of patients with HBV-related acute-on-chronic liver failure].
Zhonghua Gan Zang Bing Za Zhi, 24 (2016), pp. 207-213
[14]
K Huang , JH Hu , HF Wang , WP He , J Chen , XZ Duan , et al.
Survival and prognostic factors in hepatitis B virus-related acute-on-chronic liver failure.
[15]
Q Zhang , X Guo , S Zhao , X Pang , Y Wang , Y Zhang , et al.
Prognostic performance of clinical indices and model scorings for acute-on-chronic liver failure: A study of 164 patients.
[16]
CG Child , JG Turcotte .
Surgery and portal hypertension.
Major Probl Clin Surg, 1 (1964), pp. 1-85
[17]
RN Pugh , IM Murray-Lyon , JL Dawson , MC Pietroni , R Williams .
Transection of the oesophagus for bleeding oesophageal varices.
[18]
PS Kamath , RH Wiesner , M Malinchoc , W Kremers , TM Therneau , CL Kosberg , et al.
A model to predict survival in patients with end-stage liver disease.
[19]
SW Biggins , WR Kim , NA Terrault , S Saab , V Balan , T Schiano , et al.
Evidence-based incorporation of serum sodium concentration into MELD.
[20]
G Qin , JG Shao , B Wang , Y Shen , J Zheng , XJ Liu , et al.
Artificial liver support system improves short- and long-term outcomes of patients with HBV-associated acute-on-chronic liver failure: a single-center experience.
[21]
G Qin , JG Shao , YC Zhu , AD Xu , JH Yao , XL Wang , et al.
Population-representative Incidence of Acute-On-Chronic Liver Failure: A Prospective Cross-Sectional Study.
[22]
RS Nanchal , S Ahmad .
Infections in Liver Disease.
[23]
C Sole , E Sola , M Morales-Ruiz , G Fernandez , P Huelin , I Graupera , et al.
Characterization of Inflammatory Response in Acute-on-Chronic Liver Failure and Relationship with Prognosis.
[24]
KQ Shi , YJ Cai , Z Lin , JZ Dong , JM Wu , XD Wang , et al.
Development and validation of a prognostic nomogram for acute-on-chronic hepatitis B liver failure.

No potential conflict of interest was reported.

Copyright © 2017. CLINICS
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos